The objectives of this study are to evaluate efficacy and safety of longan extract spray (P80 spray) in volunteers with coronavirus disease 2019 (COVID19).Patients who infected COVID 19 (positive COVID 19 RT-PCR from nasal swab) are enrolled in the study. They will be treated with standard treatment of COVID 19. In addition, the patients will received longan extract nasal spray (P80 spray) or placebo nasal spray for 3 days (6 times). After that, they will be nasal swabbed for detecting COVID 19 infection. Adverse event will also be evaluated by physician or nurse.
Patients who infected COVID 19 (positive COVID 19 RT-PCR from nasal swab) and pass inclusion criteria are enrolled in the study. The patients will be checked the clinical symptoms and chest x-ray by physician. They will be treated with standard treatment of COVID 19. In addition, the patients will received longan extract nasal spray (P80 spray) or placebo nasal spray for 3 days (6 times). Physician or nurse will ask for adverse events every day. After 3 days, the patients will be nasal swabbed for detecting COVID 19 infection.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Enrollment
60
The patients will be received 2 puff of Longan nasal spray 2 times/day for 3 days.
The patients will be received 2 puff of placebo nasal spray 2 times/day for 3 days.
Nasal swab test negative
There will be a negative reverse transcriptase-polymerase chain reaction (RT-PCR) test
Time frame: 3 days
Absent of respiratory symptoms
There will be a body temperature less than 37.5 degree celsius and absent of respiratory symptoms.
Time frame: 3 days
No adverse event
There will be no allergic reaction
Time frame: 3 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.